At an 'inflection point': GentiBio reels in $157M ahead of what CEO Adel Nada sees as a Treg boom

GentiBio CEO Adel Nada says regulatory T cells (or Tregs) are now where CAR-Ts were at the beginning of the last decade — at an inflection point. With a handful of drugmakers zeroing in on the protective class of immune cells, Nada says big developments are coming. And the proof, he says, is in his company’s latest megaround.